HWKN

HAWKINS INC. - 10-Q Summary (Quarter Ended June 30, 2007)

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended June 30, 2007, for HAWKINS, INC., a Minnesota-based company operating in three segments: Industrial, Water Treatment, and Pharmaceutical. The company manufactures and distributes chemical products. As of August 9, 2007, there were 10,257,084 shares of common stock outstanding.

Key Financial Metrics

Debt and Liquidity: The company reported no long-term debt on the balance sheet. Liquidity is supported by cash, cash equivalents, and investments available-for-sale totaling approximately $22.9 million. The company paid cash dividends of $2,247,686 during the quarter.

Material Changes vs. Prior Period

• Revenue Growth: Sales increased 17.3% year-over-year, driven primarily by the Industrial segment (+25.2%) and Water Treatment segment (+8%). The Industrial increase was due to higher volumes in existing product lines, including caustic soda.
• Margin Compression: Overall gross margin percentage declined from 26.1% to 24.3%. The Industrial segment margin dropped from 21.8% to 18.8% due to a shift toward high-volume, lower-margin products. Conversely, the Water Treatment margin improved to 32.8%.
• Operating Expenses: Selling, general, and administrative (SG&A) expenses rose to $7.49 million (15.4% of sales) from $6.64 million (16.0% of sales). This increase included approximately $537,000 in ERP system implementation costs and $300,000 in acquisition-related expenses.
• Acquisition: The company completed the acquisition of Trumark, Inc. on May 31, 2007, for approximately $6 million in cash and stock. Trumark is a producer of antimicrobial products for the food industry and is included in the Industrial segment.

Outlook, Risks, and Management Commentary

• FDA Restrictions: The Pharmaceutical segment remains under restrictions from the FDA regarding certain packaging configurations and expiration dating. Approximately $60,000 (4%) of Pharmaceutical inventory is currently unsellable. Management does not expect a material impact on overall results but notes sales in the second half of fiscal 2007 were negatively impacted.
• ERP Implementation: Significant costs related to the Enterprise Resource Planning (ERP) system implementation were incurred this quarter. Management expects these consulting and contractor fees to gradually decrease in fiscal 2008.
• Commodity Pricing: The company is subject to fluctuations in commodity chemical prices. While they attempt to pass cost increases to customers, there is no assurance this will be possible in the future.
• Investment Portfolio: The company holds fixed income securities and mutual funds. Some investments were temporarily impaired with a carrying value exceeding market value by approximately $59,000, but management intends to hold them to maturity.
• Capital Needs: Management anticipates funding short and long-term needs with internally generated funds and does not expect to engage in significant financing activities.

Key Facts for Investor Verification

• Verify the timeline for resolving FDA restrictions on the Pharmaceutical segment and the potential impact on future inventory write-downs.
• Monitor the integration of the Trumark acquisition and its contribution to the Industrial segment's margins in subsequent quarters.
• Track the reduction of one-time ERP implementation costs to assess the true run-rate of SG&A expenses.
• Review the company's ability to maintain gross margins given the cyclical nature of commodity chemical prices and the shift toward lower-margin high-volume products.
• Confirm the status of the $59,000 temporarily impaired investments and the company's intent to hold them to maturity.